《公司業績》華領醫藥-B(02552.HK)半年虧損收窄至1.65億元人民幣
華領醫藥-B(02552.HK)公布截至今年6月底止中期業績,虧損收窄至1.65億元人民幣,上年同期蝕1.74億元人民幣 ;每股虧損0.17元人民幣。不派息。
至6月底止,銀行結餘及現金為約8.5億元人民幣。上半年研發開支為9,800萬元人民幣,按年減少12.7%。
展望下半年,公司計劃開展更多有關dorzagliatin以及dorzagliatin聯合用藥的研究,包括在T2D患者身上進行與達格列淨、西格列汀及GLP-1及胰島素的聯合用藥,以作高質素的血糖控制及改善TIR,此可能改善T2D的標準治療,以及在T1D患者身上就新適應症進行與胰島素的聯合用藥。亦正發展dorzagliatin的固定劑量複方製劑的管線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.